{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T10:24:07Z","timestamp":1781778247108,"version":"3.54.5"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,15]],"date-time":"2019-08-15T00:00:00Z","timestamp":1565827200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,8,15]],"date-time":"2019-08-15T00:00:00Z","timestamp":1565827200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["09\/144\/50"],"award-info":[{"award-number":["09\/144\/50"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12916-019-1395-5","type":"journal-article","created":{"date-parts":[[2019,8,15]],"date-time":"2019-08-15T01:02:21Z","timestamp":1565830941000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Clinical and cost-effectiveness of contingency management for cannabis use in early psychosis: the CIRCLE randomised clinical trial"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4905-4168","authenticated-orcid":false,"given":"Luke","family":"Sheridan Rains","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Marston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Hinton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Marwaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Craig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rumana Z.","family":"Omar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"McCrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Colman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Harder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amie","family":"Randhawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsty","family":"Labuschagne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodora","family":"Stefanidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Christoforou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Craig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Strang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Weaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,15]]},"reference":[{"key":"1395_CR1","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1192\/bjp.bp.104.007237","volume":"188","author":"TE Barnes","year":"2006","unstructured":"Barnes TE, Mutsatsa SH, Hutton SB, Watt HC, Joyce EM. Comorbid substance use and age at onset of schizophrenia. Br J Psychiatry. 2006;188:237\u201342.","journal-title":"Br J Psychiatry"},{"key":"1395_CR2","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S2215-0366(15)00363-6","volume":"3","author":"T Schoeler","year":"2016","unstructured":"Schoeler T, Monk A, Sami MB, Klamerus E, Foglia E, Brown R, et al. Continued versus discontinued cannabis use in patients with psychosis: a systematic review and meta-analysis. Lancet Psychiat. 2016;3:215\u201325.","journal-title":"Lancet Psychiat"},{"key":"1395_CR3","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1192\/bjp.bp.105.017236","volume":"189","author":"D Wade","year":"2006","unstructured":"Wade D, Harrigan S, Edwards J, Burgess PM, Whelan G, McGorry PD. Substance misuse in first-episode psychosis: 15-month prospective followup study. Br J Psychiatry. 2006;189:229\u201334.","journal-title":"Br J Psychiatry"},{"key":"1395_CR4","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1001\/archpsyc.1994.03950040017002","volume":"51","author":"D Linszen","year":"1994","unstructured":"Linszen D, Dingemans P, Lenior M. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry. 1994;51:273\u20134.","journal-title":"Arch Gen Psychiatry"},{"key":"1395_CR5","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1600-0447.2005.00554.x","volume":"112","author":"M Lambert","year":"2005","unstructured":"Lambert M, Conus P, Lubman DI, Wade D, Yuen H, Moritz S, et al. The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis. Acta Psychiatr Scand. 2005;112:141\u20138.","journal-title":"Acta Psychiatr Scand"},{"key":"1395_CR6","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1192\/bjp.180.6.490","volume":"180","author":"E Walsh","year":"2002","unstructured":"Walsh E, Buchanan A, Fahy T. Violence and schizophrenia: examining the evidence. Br J Psychiatry. 2002;180:490\u20135.","journal-title":"Br J Psychiatry"},{"key":"1395_CR7","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1192\/bjp.bp.105.020982","volume":"191","author":"S Marwaha","year":"2007","unstructured":"Marwaha S, Johnson S, Bebbington P, Stafford M, Angermeyer MC, Brugha T, et al. Rates and correlates of employment in people with schizophrenia living in the UK, France and Germany: findings from the EuroSC study. Br J Psychiatry. 2007;191:30\u20137.","journal-title":"Br J Psychiatry"},{"key":"1395_CR8","doi-asserted-by":"publisher","unstructured":"Hunt GE, Siegfried N, Morley K, Sitharthan T, Cleary M. Psychosocial interventions for people with both severe mental illness and substance misuse. Cochrane Database Syst Rev. 2013;(10):Art. No.: CD001088. \n                    https:\/\/doi.org\/10.1002\/14651858.CD001088.pub3\n                    \n                   \n                    http:\/\/www.cochrane.org\/CD001088\/SCHIZ_psychosocial-interventions-for-people-with-bothsevere-mental-illness-and-substance-misuse\n                    \n                  .","DOI":"10.1002\/14651858.CD001088.pub3"},{"key":"1395_CR9","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jaac.2015.02.009","volume":"54","author":"C Stanger","year":"2015","unstructured":"Stanger C, Ryan SR, Scherer EA, Norton GE, Budney AJ. Clinic and home-based contingency management plus parent training for adolescent cannabis use disorders. J Am Acad Child Adolesc Psychiatry. 2015;54:445\u201353.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"1395_CR10","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1037\/0022-006X.68.6.1051","volume":"68","author":"A Budney","year":"2000","unstructured":"Budney A, Higgins S, Radonovich K, Novy PL. Adding voucher-based incentive to coping skills and motivational enhancement improves outcomes during treatment for marijuana dependence. J Consult Clin Psychol. 2000;68:1051\u201361.","journal-title":"J Consult Clin Psychol"},{"key":"1395_CR11","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1037\/0022-006X.74.2.307","volume":"74","author":"AJ Budney","year":"2006","unstructured":"Budney AJ, Moore BA, Rocha HL, Higgins ST. Clinical trial of abstinence based vouchers and cognitive-behavioral therapy for cannabis dependence. J Consult Clin Psychol. 2006;74:307\u201316.","journal-title":"J Consult Clin Psychol"},{"key":"1395_CR12","doi-asserted-by":"publisher","unstructured":"Cahill K, Hartmann-Boyce J, Perera R. Incentives for smoking cessation. Cochrane Database Syst Rev. 2015;(5):Art. No.:CD004307. \n                    https:\/\/doi.org\/10.1002\/14651858.CD004307.pub5\n                    \n                  .","DOI":"10.1002\/14651858.CD004307.pub5"},{"issue":"2","key":"1395_CR13","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1192\/bjp.bp.106.022293","volume":"189","author":"NM Petry","year":"2006","unstructured":"Petry NM. Contingency management treatments. Br J Psychiatry. 2006;189(2):97\u20138.","journal-title":"Br J Psychiatry"},{"key":"1395_CR14","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1037\/a0035264","volume":"82","author":"MD Godley","year":"2014","unstructured":"Godley MD, Godley SH, Dennis ML, Funk RR, Passetti LL, Petry NM. A randomized trial of assertive continuing care and contingency management for adolescents with substance use disorders. J Consult Clin Psych. 2014;82:40\u201351.","journal-title":"J Consult Clin Psych"},{"key":"1395_CR15","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ypmed.2016.08.008","volume":"92","author":"DR Davis","year":"2016","unstructured":"Davis DR, Kurti AN, Skelly JM, Redner R, White TJ, Higgins ST. A review of the literature on contingency management in the treatment of substance use disorders, 2009\u20132014. Prev Med. 2016;92:36\u201346.","journal-title":"Prev Med"},{"key":"1395_CR16","volume-title":"Clinical guideline on drug misuse in over 16\u2019s: psychosocial interventions. Clinical Guideline 51","author":"National Institute for Health and Care Excellence (NICE)","year":"2007","unstructured":"National Institute for Health and Care Excellence (NICE). Clinical guideline on drug misuse in over 16\u2019s: psychosocial interventions. Clinical Guideline 51. London: NICE; 2007."},{"issue":"7","key":"1395_CR17","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/ajad.12558","volume":"26","author":"M McDonell","year":"2017","unstructured":"McDonell M, Leickly E, McPherson S, Skalisky J, Hirchak K, Oluwoye O, et al. Pretreatment ethyl glucuronide levels predict response to a contingency management intervention for alcohol use disorders among adults with serious mental illness. Am J Addict. 2017;26(7):673\u20135.","journal-title":"Am J Addict"},{"key":"1395_CR18","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1176\/appi.ajp.2012.11121831","volume":"170","author":"MG McDonell","year":"2013","unstructured":"McDonell MG, Srebnik D, Angelo F, McPherson S, Lowe JM, Sugar A, et al. Randomized controlled trial of contingency management for stimulant use in community mental health patients with serious mental illness. Am J Psychiat. 2013;170:94\u2013101.","journal-title":"Am J Psychiat"},{"issue":"2","key":"1395_CR19","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00213-011-2282-8","volume":"217","author":"J Tidey","year":"2011","unstructured":"Tidey J, Rohsenow D, Kaplan G, Swift R, Reid N. Effects of contingency management and bupropion on cigarette smoking in smokers with schizophrenia. Psychopharmacol. 2011;217(2):279\u201387.","journal-title":"Psychopharmacol"},{"key":"1395_CR20","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.drugalcdep.2015.05.004","volume":"153","author":"SM Murphy","year":"2015","unstructured":"Murphy SM, McDonell MG, McPherson S, Srebnik D, Angelo F, Roll JM, et al. An economic evaluation of a contingency-management intervention for stimulant use among community mental health patients with serious mental illness. Drug Alcohol Depen. 2015;153:293\u20139.","journal-title":"Drug Alcohol Depen"},{"key":"1395_CR21","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1001\/archpsyc.63.4.426","volume":"63","author":"AS Bellack","year":"2006","unstructured":"Bellack AS, Bennett ME, Gearon JS, Brown CH, Ye Yang MS. A randomized clinical trial of a new behavioral treatment for drug abuse in people with severe and persistent mental illness. Arch Gen Psychiatry. 2006;63:426\u201332.","journal-title":"Arch Gen Psychiatry"},{"key":"1395_CR22","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1037\/1064-1297.8.4.509","volume":"8","author":"SC Sigmon","year":"2000","unstructured":"Sigmon SC, Steingard S, Badger GJ, Anthony SL, Higgins ST. Contingent reinforcement of marijuana abstinence among individuals with serious mental illness: a feasibility study. Exp Clin Psychopharmacol. 2000;8:509\u201317.","journal-title":"Exp Clin Psychopharmacol"},{"key":"1395_CR23","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jsat.2006.02.001","volume":"30","author":"SC Sigmon","year":"2006","unstructured":"Sigmon SC, Higgins ST. Voucher-based contingent reinforcement of marijuana abstinence among individuals with serious mental illness. J Subst Abus Treat. 2006;30:291\u20135.","journal-title":"J Subst Abus Treat"},{"key":"1395_CR24","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.schres.2017.05.006","volume":"194","author":"R Rabin","year":"2018","unstructured":"Rabin R, Kozak K, Zakzanis K, Remington G, Stefan C, Budney A, et al. A method to achieve extended cannabis abstinence in cannabis dependent patients with schizophrenia and non-psychiatric controls. Schizophr Res. 2018;194:47\u201354.","journal-title":"Schizophr Res"},{"key":"1395_CR25","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jsat.2007.03.006","volume":"34","author":"R Secades-Villa","year":"2008","unstructured":"Secades-Villa R, Garc\u00eda-Rodr\u00edguez O, Higgins S, Fern\u00e1ndez-Hermida JR, Carballo JL. Community reinforcement approach plus vouchers for cocaine dependence in a community setting in Spain: six-month outcomes. J Subst Abus Treat. 2008;34:202\u20137.","journal-title":"J Subst Abus Treat"},{"key":"1395_CR26","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0140-6736(14)60196-3","volume":"384","author":"T Weaver","year":"2014","unstructured":"Weaver T, Metrebian N, Hellier J, Pilling S, Charles V, Little N, et al. Use of contingency management incentives to improve completion of hepatitis B vaccination in people undergoing treatment for heroin dependence: a cluster randomised trial. Lancet. 2014;384:153\u201363.","journal-title":"Lancet."},{"key":"1395_CR27","doi-asserted-by":"crossref","first-page":"f5847","DOI":"10.1136\/bmj.f5847","volume":"347","author":"S Priebe","year":"2013","unstructured":"Priebe S, Yeeles K, Bremner S, Lauber C, Eldridge S, Ashby D, et al. Effectiveness of financial incentives to improve adherence to maintenance treatment with antipsychotics: cluster randomised controlled trial. BMJ. 2013;347:f5847.","journal-title":"BMJ."},{"key":"1395_CR28","volume-title":"NHS England, and the National Collaborating Centre for Mental Health, Implementing the Early Intervention in Psychosis Access and Waiting Time Standard: Guidance","author":"NICE","year":"2016","unstructured":"NICE, NHS England, and the National Collaborating Centre for Mental Health, Implementing the Early Intervention in Psychosis Access and Waiting Time Standard: Guidance, 2016."},{"key":"1395_CR29","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1186\/s13063-016-1620-x","volume":"17","author":"S Johnson","year":"2016","unstructured":"Johnson S, Sheridan Rains L, Marwaha S, et al. A randomised controlled trial of the clinical and cost-effectiveness of a contingency management intervention compared to treatment as usual for reduction of cannabis use and of relapse in early psychosis (CIRCLE): a study protocol for a randomised controlled trial. Trials. 2016;17:515.","journal-title":"Trials"},{"key":"1395_CR30","volume-title":"Measuring alcohol consumption: psychosocial and biological methods","author":"L Sobell","year":"1992","unstructured":"Sobell L, Sobell M. Timeline follow-back. In: Allen J, Litten R, editors. Measuring alcohol consumption: psychosocial and biological methods. New Jersey: Humana Press; 1992."},{"key":"1395_CR31","first-page":"23","volume":"5","author":"PL Cary","year":"2005","unstructured":"Cary PL. The marijuana detection window: determining the length of time cannabinoids will remain detectable in urine following smoking: a critical review of relevant research and cannabinoid detection guidance for drug courts. Drug Court Rev. 2005;5:23\u201358.","journal-title":"Drug Court Rev"},{"issue":"2","key":"1395_CR32","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261\u201376.","journal-title":"Schizophr Bull"},{"key":"1395_CR33","volume-title":"Measuring mental health needs","author":"J Beecham","year":"2001","unstructured":"Beecham J, Knapp M. Costing psychiatric interventions. In: Thornicroft G, editor. Measuring mental health needs. London: Gaskell; 2001."},{"key":"1395_CR34","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/01.mlr.0000135827.18610.0d","volume":"42","author":"JE Brazier","year":"2004","unstructured":"Brazier JE, Roberts JR. The estimation of a preference-based index from the SF-12. Med Care. 2004;42:851\u20139.","journal-title":"Med Care"},{"key":"1395_CR35","first-page":"27","volume":"12","author":"P McCrone","year":"2009","unstructured":"McCrone P, Patel A, Knapp M, Schene A, Koeter M, Ammadeo F, et al. A comparison of SF-6D and EQ-5D utility scores in a study of patients with schizophrenia. J Ment Health Policy Econ. 2009;12:27\u201331.","journal-title":"J Ment Health Policy Econ"},{"key":"1395_CR36","volume-title":"Stata Statistical Software: Release 11","author":"StataCorp","year":"2009","unstructured":"StataCorp. Stata Statistical Software: Release 11. College Station: StataCorp LP; 2009."},{"key":"1395_CR37","volume-title":"Modelling survival data in medical research","author":"D Collett","year":"2014","unstructured":"Collett D. Modelling survival data in medical research. 3rd ed. Hoboken: Chapman and Hall; 2014.","edition":"3"},{"issue":"4","key":"1395_CR38","doi-asserted-by":"crossref","first-page":"817","DOI":"10.2307\/1912934","volume":"48","author":"H White","year":"1980","unstructured":"White H. A Heteroskedasticity-consistent covariance matrix estimator and a direct test for Heteroskedasticity. Econometrica. 1980;48(4):817.","journal-title":"Econometrica."},{"key":"1395_CR39","volume-title":"Stata statistical software: release 14","author":"StataCorp","year":"2015","unstructured":"StataCorp. Stata statistical software: release 14. College Station: StataCorp LP; 2015."},{"issue":"3","key":"1395_CR40","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S2215-0366(14)00117-5","volume":"2","author":"M Di Forti","year":"2015","unstructured":"Di Forti M, Marconi A, Carra E, Fraietta S, Trotta A, Bonomo M, et al. Proportion of patients in South London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. Lancet Psychiatry. 2015;2(3):233\u20138.","journal-title":"Lancet Psychiatry"},{"issue":"5","key":"1395_CR41","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S2215-0366(19)30048-3","volume":"6","author":"M Di Forti","year":"2019","unstructured":"Di Forti M, Quattrone D, Freeman T, Tripoli G, Gayer-Anderson C, Quigley H, et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry. 2019;6(5):427\u201336.","journal-title":"Lancet Psychiatry"},{"key":"1395_CR42","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.eurpsy.2011.03.001","volume":"27","author":"BG Schimmelmann","year":"2012","unstructured":"Schimmelmann BG, Conus P, Cotton S, Kupferschmid S, McGorry PD, Lambert M. Prevalence and impact of cannabis use disorders in adolescents with early onset first episode psychosis. Eur Psychiat. 2012;27:463\u20139.","journal-title":"Eur Psychiat"},{"issue":"1","key":"1395_CR43","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jsat.2006.12.034","volume":"34","author":"C DiClemente","year":"2008","unstructured":"DiClemente C, Nidecker M, Bellack A. Motivation and the stages of change among individuals with severe mental illness and substance abuse disorders. J Subst Abuse Treat. 2008;34(1):25\u201335.","journal-title":"J Subst Abuse Treat"},{"key":"1395_CR44","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jsat.2015.09.006","volume":"61","author":"M Priester","year":"2016","unstructured":"Priester M, Browne T, Iachini a c S, DeHart D, Seay K. Treatment access barriers and disparities among individuals with co-occurring mental health and substance use disorders: an integrative literature review. J Subst Abus Treat. 2016;61:47\u201359.","journal-title":"J Subst Abus Treat"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-019-1395-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12916-019-1395-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-019-1395-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T23:14:05Z","timestamp":1597360445000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-019-1395-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,15]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1395"],"URL":"https:\/\/doi.org\/10.1186\/s12916-019-1395-5","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,15]]},"assertion":[{"value":"23 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval for the trial was received on 16 March 2012 from the London \u2013 South East National Research Ethics Service committee (REC reference 11\/LO\/1939). All participants provided written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This trial was funded by the National Institute for Health Research, Health Technology Assessment programme (09\/144\/50), and MK is a member of CTUs funded by NIHR and the Rapid Trials and Add-on Studies Board. RM is a member of the HTA General Board. JS is supported by the National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health at South London and Maudsley NHS Foundation Trust and King\u2019s College London. JS reports grants from Camurus (Lund, Sweden), Martindale Pharma (now Ethypharm UK, Woodburn Green, UK), Mundipharma (Mundipharma International Limited, Cambridge, UK) and Braeburn Pharma (Braeburn Inc., Plymouth Meeting, PA, USA), and other from Martindale Pharma, Braeburn Pharma outside the submitted work. In addition, John Strang has patents unrelated to the work described in this article: a patent Euro-Celtique issued and a patent King\u2019s College London pending.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"161"}}